Grief & Loss: Radio Times Personal Story
ASPR decisively invests $375 million in shionogi, Inc. to fast-track a groundbreaking COVID-19 prevention drug. This strategic move directly targets enhancing protection for immunocompromised individuals, bolstering crucial COVID-19 prevention measures. The drug’s chief role is to fortify the defenses of those most susceptible, adding a vital shield. This update, disseminated by News Directory 3, underscores the proactive measures to safeguard public health.It represents a vital step in the ongoing fight against the virus. Learn about the innovative approach and critical financial backing driving this critical advancement. Discover what’s next …
ASPR Funds Shionogi for COVID-19 Prevention Drug development
Updated June 19, 2025
The Administration for strategic Preparedness and Response (ASPR) is investing $375 million in Shionogi, Inc. to facilitate the development of a new drug aimed at COVID-19 prevention. This initiative focuses on protecting individuals wiht compromised immune systems, enhancing COVID-19 prevention strategies.
The COVID-19 prevention drug is specifically designed for those who are especially vulnerable to infection due to weakened immunity. The role of the drug will be to provide an extra layer of protection for this high-risk population.